Your browser is no longer supported. Please, upgrade your browser.
Settings
PRFX [NASD]
PainReform Ltd.
Index- P/E- EPS (ttm)- Insider Own23.10% Shs Outstand10.06M Perf Week-10.00%
Market Cap42.56M Forward P/E- EPS next Y-1.50 Insider Trans0.00% Shs Float- Perf Month-25.53%
Income- PEG- EPS next Q-0.56 Inst Own38.73% Short Float- Perf Quarter1.93%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio0.18 Perf Half Y-13.67%
Book/sh- P/B- EPS next Y26.50% ROA- Target Price- Perf Year-
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range3.82 - 7.85 Perf YTD-5.37%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-48.54% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low5.76% ATR0.44
Employees1 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)36.17 Volatility5.16% 8.71%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.26 Prev Close4.23
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume206.57K Price4.04
Recom2.00 SMA20-13.14% SMA50-22.45% SMA200-17.89% Volume38,931 Change-4.49%
Mar-18-21 09:15AM  
Mar-11-21 10:43AM  
Mar-08-21 09:00AM  
Jan-07-21 08:30AM  
Jan-06-21 08:30AM  
Jan-04-21 08:30AM  
Nov-23-20 08:30AM  
Nov-12-20 09:00AM  
Nov-05-20 08:30AM  
Oct-19-20 09:00AM  
Sep-29-20 07:30AM  
Sep-09-20 02:15PM  
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.